Journal
NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 24, Issue 7, Pages 578-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb.3414
Keywords
-
Funding
- Cancer Research UK [C596/A17196]
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [647849]
- Cancer Research UK [18274, S_2742, 23278] Funding Source: researchfish
- The Francis Crick Institute [10557] Funding Source: researchfish
Ask authors/readers for more resources
MDM2-MDMX complexes bind the p53 tumor-suppressor protein, inhibiting p53's transcriptional activity and targeting p53 for proteasomal degradation. Inhibitors that disrupt binding between p53 and MDM2 efficiently activate a p53 response, but their use in the treatment of cancers that retain wild-type p53 may be limited by on-target toxicities due to p53 activation in normal tissue. Guided by a novel crystal structure of the MDM2-MDMX-E2(UbcH5B)-ubiquitin complex, we designed MDM2 mutants that prevent E2-ubiquitin binding without altering the RING-domain structure. These mutants lack MDM2's E3 activity but retain the ability to limit p53's transcriptional activity and allow cell proliferation. Cells expressing these mutants respond more quickly to cellular stress than cells expressing wild-type MDM2, but basal p53 control is maintained. Targeting the MDM2 E3-ligase activity could therefore widen the therapeutic window of p53 activation in tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available